Cell Signaling Technology Logo - Extra Large
1% for the planet logo
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

BRD1 (F8X6N) Rabbit mAb #68436

Filter:
  • WB
  • ChIP

    Product Specifications

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 130, 150
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • ChIP-Chromatin Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    For optimal ChIP results, use 10 μL of antibody and 10 μg of chromatin (approximately 4 × 106 cells) per IP. This antibody has been validated using SimpleChIP® Enzymatic Chromatin IP Kits.
    Application Dilution
    Western Blotting 1:1000
    Chromatin IP 1:100

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    BRD1 (F8X6N) Rabbit mAb recognizes endogenous levels of total BRD1 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant protein specific to human BRD1 protein.

    Background

    Bromodomain-containing protein 1 (BRD1), also known as BRPF2, is part of a histone acetyltransferase complex along with HBO1 that is responsible for global acetylation of Lys14 on histone H3 (1). BRD1 contains a unique PHD finger domain with a positively charged surface, which can bind DNA non-specifically via interaction with histone H3 (2,3). By driving histone acetylation around key genes, BRD1 has been implicated in many cellular functions, including stem cell differentiation, T-cell development, and erythropoiesis (1,4,5). The BRD1 gene has been shown to confer susceptibility to schizophrenia and bipolar disorder (6,7). BRD1 overexpression has been described in colorectal cancer, and BRD1 inhibition has been shown to increase immune therapy efficacy in high-grade ovarian cancer (8,9).
    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.